<DOC>
	<DOCNO>NCT01906684</DOCNO>
	<brief_summary>This study determine change : 1 ) immune activity , characterize `` immunorepertoire ; '' 2 ) 7 Tesla MRI brain image ; 3 ) clinical outcome ; 4 ) patient report quality life outcome subject relapsing-remitting multiple sclerosis treat Acthar Gel .</brief_summary>
	<brief_title>Comprehensive Analysis Relapse Multiple Sclerosis</brief_title>
	<detailed_description>20 patient documented Multiple Sclerosis , diagnose within 12 month enrollment study currently experience MS relapse , define follow manifestation : Acute onset worsen manifestation CNS relapse ( exclude spinal cord ) include : - Brain stem syndrome - Optic neuritis - Cerebellar syndrome If choose participate , subject ask : Meet Clinic 4 time : - Initial visit - 5 day baseline visit - 14 day baseline visit - 30 day baseline visit Meet neurologist neurological exam include : - Review neurological status - Review new ongoing symptom - Review symptom resolution - Review side effect adverse event - Resolution patient question concern - Provide 40cc whole blood sample At 4 visit - Consent Acthar Gel treatment relapse 14 day ( require relapse ) - Ss agree train self-administration Acthar - First dose administer Baseline visit - Self-administered day 2-14 participation - Complete 4 psychometric instrument At baseline 30 day visit - Cognitive assessment use Brief International Cognitive Assessment MS ( Benedict 2012 ) - Administered Tanner Center Staff specially train assessment - Quality Life assessment : self-administered - MSQoL ( Cella et al , 1006 ) - Psychological Adjustment Illness Survey ( Rodrigue et al 2000 ) - Coping Skills Inventory ( Liveneh , 2003 ) - Participate brief semi-structured interview , Day 5 visit</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<criteria>Patients eligible participate study : They diagnose RelapsingRemitting Multiple Sclerosis within 1 year participation study Are establish patient Tanner Center MS Seek care relapse within 72 hour onset Are age 19 65 inclusively . Relapse confirm define acute worsen function last least 24 hour manifestation Central Nervous System relapse ( exclude spinal cord ) include : Brain stem syndrome Optic neuritis Cerebellar syndromes Hemimotor/sensory event Males Females eligible Patients race ethnicity eligible Are pregnant ( confirmed pregnancy test time enrollment ) nursing Have know contraindicating condition ( see exclusion ) Potential participant exclude meet criterion , also : They currently treat MS follow diseasemodifying drug : Tysabri , Gilenya , Aubagio , Tecfidera They history experience significant adverse reaction corticosteroid They deem Dr Riser well serve intervention Acthar Gel treat current MS relapse Are pregnant nursing Are know contraindicate condition : Scleroderm Osteoporosis Systemic fungal infection Ocular herpes simplex Recent surgery History presence peptic ulcer Congestive heart failure Uncontrolled hypertension Adrenocortical insufficiency , hyperfunction sensitivity Sensitivity proteins porcine origin</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Acthar Gel</keyword>
	<keyword>MS relapse</keyword>
	<keyword>7T MRI imaging</keyword>
	<keyword>Quality Life</keyword>
</DOC>